{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:48:58Z","timestamp":1757591338921},"reference-count":82,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.leukres.2008.10.001","type":"journal-article","created":{"date-parts":[[2008,11,15]],"date-time":"2008-11-15T09:42:39Z","timestamp":1226742159000},"page":"617-623","source":"Crossref","is-referenced-by-count":6,"title":["Preclinical and clinical experience with dasatinib in philadelphia chromosome-negative leukemias and myeloid disorders"],"prefix":"10.1016","volume":"33","author":[{"given":"Srdan","family":"Verstovsek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2008.10.001_bib1","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2008.10.001_bib2","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.10.001_bib3","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1002\/cncr.20211","article-title":"Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders","volume":"100","author":"Cortes","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2008.10.001_bib4","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2008.10.001_bib5","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.leukres.2008.10.001_bib6","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1093\/annonc\/mdm086","article-title":"The role of Src in prostate cancer","volume":"18","author":"Fizazi","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.leukres.2008.10.001_bib7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.leukres.2008.10.001_bib8","first-page":"920","article-title":"KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication","volume":"89","author":"Beghini","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2008.10.001_bib9","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.leukres.2008.10.001_bib10","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":"Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.10.001_bib11","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.10.001_bib12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","article-title":"Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies","volume":"66","author":"Schittenhelm","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2008.10.001_bib13","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","article-title":"Dasatinib (BMS-354825) inhibits KITD816 V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","volume":"108","author":"Shah","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.10.001_bib14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.10.001_bib15","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997","volume":"17","author":"Harris","year":"1999","journal-title":"Clin Oncol"},{"key":"10.1016\/j.leukres.2008.10.001_bib16","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","article-title":"Acute myeloid leukaemia","volume":"368","author":"Estey","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2008.10.001_bib17","doi-asserted-by":"crossref","first-page":"6285","DOI":"10.1200\/JCO.2005.05.010","article-title":"Genetics of myeloid malignancies: pathogenetic and clinical implications","volume":"23","author":"Frohling","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2008.10.001_bib18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.10.001_bib19","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/asheducation-2005.1.156","article-title":"Molecular pathogenesis of MDS","author":"Look","year":"2005","journal-title":"Am Soc Hematol Educ Program"},{"key":"10.1016\/j.leukres.2008.10.001_bib20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3324\/haematol.11374","article-title":"Myelodysplastic\/myeloproliferative disorders","volume":"93","author":"Malcovati","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2008.10.001_bib21","first-page":"1513","article-title":"Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches","volume":"91","author":"Deschler","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2008.10.001_bib22","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1182\/blood.V92.2.596","article-title":"The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL)","volume":"92","author":"Bene","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.10.001_bib23","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1002\/cncr.11416","article-title":"Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders","volume":"97","author":"Cortes","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2008.10.001_bib24","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1200\/JCO.2006.06.9500","article-title":"Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study","volume":"24","author":"Paschka","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2008.10.001_bib25","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood-2005-04-1466","article-title":"KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival","volume":"107","author":"Schnittger","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.10.001_bib26","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3324\/haematol.13345","article-title":"Molecular characterization of acute myeloid leukemia","volume":"93","author":"Dohner","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2008.10.001_bib27","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.leukres.2006.02.008","article-title":"Mutational analysis of the KIT gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia","volume":"30","author":"Lorenzo","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2008.10.001_bib28","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2007-04-082099","article-title":"A critical role for Lyn in acute myeloid leukemia","volume":"111","author":"Dos Santos","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.10.001_bib29","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.leukres.2007.11.032","article-title":"Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT)","volume":"32","author":"Ozawa","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2008.10.001_bib30","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/sj.leu.2404547","article-title":"Lyn is an important component of the signal transduction pathway specific to FLT3\/ITD and can be a therapeutic target in the treatment of AML with FLT3\/ITD","volume":"21","author":"Okamoto","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.10.001_bib31","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2008.10.001_bib32","first-page":"0923","article-title":"Dasatinib in children and adolescents with relapsed or refractory leukemia: preliminary results of the CA180018 Phase I\/II study from the ITCC consortium","volume":"93","author":"Zwaan","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2008.10.001_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1750-1172-2-3","article-title":"Essential thrombocythemia","volume":"2","author":"Briere","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.leukres.2008.10.001_bib34","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"The myeloproliferative disorders","volume":"355","author":"Campbell","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2008.10.001_bib35","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/ajh.21183","article-title":"Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy","volume":"83","author":"Tefferi","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2008.10.001_bib36","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1182\/blood.V74.7.2330.2330","article-title":"Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders","volume":"74","author":"Gersuk","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.10.001_bib37","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00000441-200303000-00007","article-title":"Polycythemia vera responds to imatinib mesylate","volume":"325","author":"Jones","year":"2003","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.leukres.2008.10.001_bib38","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/sj.leu.2402938","article-title":"Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera","volume":"17","author":"Silver","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.10.001_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-007-0403-6","article-title":"The diagnosis of BCR\/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers","volume":"87","author":"Haferlach","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2008.10.001_bib40","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1371\/journal.pone.0000018","article-title":"Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F","volume":"1","author":"Zaleskas","year":"2006","journal-title":"PLoS ONE"},{"key":"10.1016\/j.leukres.2008.10.001_bib41","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.exphem.2007.03.012","article-title":"Imatinib effect on growth and signal transduction in polycythemia vera","volume":"35","author":"Gaikwad","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2008.10.001_bib42","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1158\/1535-7163.MCT-06-0446","article-title":"Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells","volume":"6","author":"Nam","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.leukres.2008.10.001_bib43","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2362.2008.01982.x","article-title":"Dasatinib inhibits progenitor cell proliferation from polycythaemia vera","volume":"38","author":"Wappl","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.leukres.2008.10.001_bib44","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/jcp.55.11.862","article-title":"Chronic neutrophilic leukaemia: 14 new cases of an uncommon myeloproliferative disease","volume":"55","author":"Bohm","year":"2002","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.leukres.2008.10.001_bib45","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1750-1172-2-37","article-title":"Hypereosinophilic syndromes","volume":"2","author":"Roufosse","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.leukres.2008.10.001_bib46","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.leukres.2005.11.011","article-title":"FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature","volume":"30","author":"Pardanani","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2008.10.001_bib47","doi-asserted-by":"crossref","first-page":"553","DOI":"10.4065\/81.4.553","article-title":"Atypical myeloproliferative disorders: diagnosis and management","volume":"81","author":"Tefferi","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2008.10.001_bib48","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.leukres.2003.10.006","article-title":"Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders","volume":"28","author":"Pardanani","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2008.10.001_bib49","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3324\/haematol.11420","article-title":"The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study","volume":"92","author":"Baccarani","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2008.10.001_bib50","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2008.10.001_bib51","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.exphem.2008.04.017","article-title":"Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha","volume":"36","author":"Baumgartner","year":"2008","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2008.10.001_bib52","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood.V110.11.60.60","article-title":"Identification of a novel TEL-Lyn fusion gene in chronic eosinophilic leukemia with ins (12;8)(p13;q11q21): effect on myeloproliferative transformation and induction of myelofibrosis","volume":"110","author":"Tanaka","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.10.001_bib53","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2008.10.001_bib54","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1046\/j.1365-2141.2003.04575.x","article-title":"Diagnosis and treatment of systemic mastocytosis: state of the art","volume":"122","author":"Valent","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.10.001_bib55","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","article-title":"Imatinib for systemic mast-cell disease","volume":"362","author":"Pardanani","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2008.10.001_bib56","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1182\/blood.V110.11.3562.3562","article-title":"Response to dasatinib in patients with aggressive systemic mastocytosis with D816 V kit mutation","volume":"110","author":"Rondoni","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.10.001_bib57","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1182\/blood.V110.11.4656.4656","article-title":"Systemic mastocytosis with c-KITD816 V mutation treated with dasatinib","volume":"110","author":"Benz","year":"2007","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2008.10.001_bib58","first-page":"1285","article-title":"Dasatinib is effective and safe in systemic mastocytosis with D816 V mutation: case report of two patients","volume":"93","author":"Pregno","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2008.10.001_bib59","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1600-0609.2008.01048.x","article-title":"Dasatinib therapy for systemic mastocytosis: four cases","volume":"80","author":"Purtill","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2008.10.001_bib60","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood.V110.11.1541.1541","article-title":"Delineation of a KIT-independent oncogenic pathway in neoplastic mast cells that involves Lyn and Btk, and can be disrupted by the KIT\/Lyn\/Btk-targeting drug dasatinib","volume":"110","author":"Gleixner","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.10.001_bib61","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3324\/haematol.11339","article-title":"Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT","volume":"92","author":"Gleixner","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2008.10.001_bib62","unstructured":"National Cancer Institute (NCI). Myelodysplastic\/myeloproliferative diseases treatment (PDQ\u00ae). Available at http:\/\/www.cancer.gov\/cancertopics\/pdq\/treatment\/mds-mpd\/ (accessed August 2008)."},{"key":"10.1016\/j.leukres.2008.10.001_bib63","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood-2005-05-1800","article-title":"JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia","volume":"106","author":"Jelinek","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.10.001_bib64","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.2007.15.3841","article-title":"Eosinophilia with FIP1L1-PDGFRA fusion in a patient with chronic myelomonocytic leukemia","volume":"26","author":"Zota","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.leukres.2008.10.001_bib65","first-page":"0665","article-title":"EPHA3 is abnormally expressed in chronic myeloproliferative disorders and can be targeted by dasatinib or by monoclonal antibodies","volume":"92","author":"Cilloni","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2008.10.001_bib66","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000046639","article-title":"The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1","volume":"107","author":"Macdonald","year":"2002","journal-title":"Acta Haematol"},{"key":"10.1016\/j.leukres.2008.10.001_bib67","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1182\/blood.V90.8.3136","article-title":"Molecular characterization of the t(8;13)(p11;q12) translocation associated with an atypical myeloproliferative disorder: evidence for three discrete loci involved in myeloid leukemias on 8p11","volume":"90","author":"Still","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.10.001_bib68","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4161\/cc.6.5.3919","article-title":"Oncogenes in myeloproliferative disorders","volume":"6","author":"Tefferi","year":"2007","journal-title":"Cell Cycle"},{"key":"10.1016\/j.leukres.2008.10.001_bib69","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cancergencyto.2007.10.021","article-title":"Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders","volume":"181","author":"Gallagher","year":"2008","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.leukres.2008.10.001_bib70","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2008.10.001_bib71","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Pui","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2008.10.001_bib72","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","article-title":"Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.10.001_bib73","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood-2007-02-073528","article-title":"Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study","volume":"110","author":"Ottmann","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.10.001_bib74","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/leu.2008.80","article-title":"Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies","volume":"22","author":"Quintas-Cardama","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.10.001_bib75","series-title":"Proceedings of the 98th Annual Meeting of the American Association for Cancer Research","article-title":"The dual ABL\/SRC inhibitors dasatinib, SKI-606, and INNO-406 are potent inhibitors of T cell acute lymphoblastic leukemia cell lines expressing the NUP214-ABL1 fusion kinase","author":"Quintas-Cardama","year":"2007"},{"key":"10.1016\/j.leukres.2008.10.001_bib76","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0140-6736(08)60456-0","article-title":"Chronic lymphocytic leukaemia","volume":"371","author":"Dighiero","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2008.10.001_bib77","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1182\/blood-2007-11-123984","article-title":"The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes","volume":"112","author":"Veldurthy","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.10.001_bib78","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1172\/JCI200522094","article-title":"Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis","volume":"115","author":"Contri","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.leukres.2008.10.001_bib79","series-title":"Proceedings of the 98th Annual Meeting of the American Association for Cancer Research","article-title":"Dasatinib sensitizes chronic lymphocytic leukemia lymphocytes to chemotherapeutic agents","author":"Goulet","year":"2007"},{"key":"10.1016\/j.leukres.2008.10.001_bib80","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1182\/blood.V110.11.4197.4197","article-title":"Significant activity of dasatinib in CLL demonstrated by ex-vivo assay","volume":"110","author":"Sigal","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.10.001_bib81","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood.V110.11.1116.1116","article-title":"Dasatinib induces apoptosis in chronic lymphocytic leukemia and enhances the activity of rituximab and fludarabine","volume":"110","author":"Aguillon","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.10.001_bib82","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1182\/blood.V110.11.3126.3126","article-title":"A phase II study of dasatinib in relapsed and refractory chronic lymphocytic leukemia (CLL\/SLL)","volume":"110","author":"Amrein","year":"2007","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521260800461X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521260800461X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T08:28:29Z","timestamp":1589099309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521260800461X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":82,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S014521260800461X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2008.10.001","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}